EUVIMEDEUVIMED entdecken
Open Access

The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig

Patricia A Hahn iD, Siddhartha Shandilya, Lucas A B da Costa, Laura C F da Silva iD, Daniel O'Hagan, Brian Liang, Kathleen Engelman, Matthew R Gardner, Guangping Gao, Sebastian P Fuchs, Jose M Martinez-Navio, Ronald C Desrosiers und 3 weitere

AIDS Research and Human Retroviruses · 2025

DOI: 10.1177/08892229251370763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, 2025. Verfasst von Patricia A Hahn und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA. Hauptthemen laut MEDLINE: Abatacept, Dependovirus, HIV-1, Antibodies, Neutralizing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adeno-associated virus (AAV)-vectored delivery of HIV-1 broadly neutralizing antibodies (bNAbs) holds promise for achieving durable HIV-1 immunity in a practical and scalable way, yet AAV-encoded bNAbs often elicit antidrug antibody (ADA) responses that limit transgene expression. Engagement of T cell-expressed CD28 with its ligands CD80/CD86 on professional antigen-presenting cells is crucial for initiating adaptive immunity. Because the immunoglobulin-fusion protein CTLA4Ig can outcompete CD28 for binding to CD80/CD86, CTLA4Ig can inhibit T cell activation and prevent immune responses. Hence, we hypothesized that co-delivering CTLA4Ig during AAV/bNAb administration would prevent ADAs in primates. Six rhesus macaques (RMs) were treated intramuscularly with AAV-1 vectors encoding “rhesusized” (rh) versions of the bNAbs 3BNC117 (IgG1) and 10-1074 (IgG2). The experimental monkeys ( n = 3) were dosed intravenously with 20 mg/kg of rh-CTLA4Ig on days 0, 2, 7, and 14, while the control animals ( n = 3) did not receive any additional intervention. The experimental monkeys mounted ADAs that inhibited bNAb expression, albeit at different rates for rh-3BNC117-IgG1 (66%) and rh-10-1074-IgG2 (33%). In the control group, the incidence of ADAs leading to loss of bNAb expression was 100% for rh-3BNC117-IgG1 and 0% for rh-10-1074-IgG2. There was no significant difference between the groups in their cumulative levels of ADAs or bNAb expression measured over 20 weeks. Despite the development of ADAs against rh-3BNC117-IgG1 in five out of six animals, and in one out of six against rh-10-1074-IgG2, macaques in both groups exhibited minimal T cell responses to both bNAbs. AAV-1 capsid-specific CD4 + T cells trended higher in the control animals. In conclusion, a short course rh-CTLA4Ig did not significantly reduce the immunogenicity of AAV-encoded bNAbs in RMs. Although our study was not powered to detect marginal effects, robust improvements in AAV-driven expression of hypermutated HIV-1 bNAbs may require combination approaches, such as multiple co-stimulation blockers, pharmacological immunosuppression, and/or muscle-specific promoters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptDependovirusHIV-1Antibodies, NeutralizingHIV AntibodiesImmunologic FactorsHIV InfectionsAnimalsMacaca mulattaGenetic VectorsMale

Stichwörter der Autor:innen

CTLA4Igadeno-associated virusbroadly neutralizing antibodies

Substanzen

AbataceptAntibodies, NeutralizingHIV AntibodiesImmunologic Factors

Autor:innen und Institutionen

  • Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
  • The Skaggs Graduate School, The Scripps Research Institute, Jupiter, Florida, USA.
  • Nonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Medicine, Division of Infectious Disease, Emory School of Medicine, Atlanta, Georgia, USA.
  • Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
  • Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

ORCID-Profile: Patricia A Hahn, Laura C F da Silva

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Hahn, P. A., Shandilya, S., da Costa, L. A. B., da Silva, L. C. F., O'Hagan, D., Liang, B., Engelman, K., Gardner, M. R., Gao, G., Fuchs, S. P., Martinez-Navio, J. M., Desrosiers, R. C., Ardeshir, A., Magnani, D. M., & Martins, M. A. (2025). The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig. AIDS Research and Human Retroviruses. https://doi.org/10.1177/08892229251370763

Vancouver

Hahn PA, Shandilya S, da Costa LAB, da Silva LCF, O'Hagan D, Liang B, et al. The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig. AIDS Research and Human Retroviruses. 2025. doi:10.1177/08892229251370763

BibTeX
@article{Hahn2025,
  author = {Hahn, Patricia A and Shandilya, Siddhartha and da Costa, Lucas A B and da Silva, Laura C F and O'Hagan, Daniel and Liang, Brian and Engelman, Kathleen and Gardner, Matthew R and Gao, Guangping and Fuchs, Sebastian P and Martinez-Navio, Jose M and Desrosiers, Ronald C and Ardeshir, Amir and Magnani, Diogo M and Martins, Mauricio A},
  title = {The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig},
  journal = {AIDS Research and Human Retroviruses},
  year = {2025},
  doi = {10.1177/08892229251370763}
}
Kostenlos starten →